Strategic Business Analysis - Group Case Study
Introduction AstraZeneca PLC (AstraZeneca, AZN:NYSE, AZN:LSE) is one of the largest pharmaceutical companies in the world. It was formed in 1999 from the merger of Sweden’s Astra AB and UK’s Zeneca Group plc. Core Activities AstraZeneca is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. One of the key benefits of the merger between Astra and Zeneca is seen as their portfolio of new products in development: AstraZeneca call this their 'product pipeline'. …show more content…
Two new product submissions delivered. Overall pipeline volume increased by 5% and in-phase distribution of our projects has improved: FGLP (32); Phase I (34); Phase II (31); Phase III (10); Life-cycle management (23). Over 300 Discovery collaborations/partnerships to access new science and technology platforms. 21 in-licensing deals, alliances and collaborations successfully concluded. R&D investment $5.2 billion.
o o o o o
o o o
2008 PERFORMANCE o SUMMARY o o o
o o o
Compiled by Rexford Sam
Group Case Study – Strategic Business Analysis (Re-Sit 2010)
GROW THE BUSINESS To maintain our position among the industry world leaders through a continued focus on driving commercial excellence.
o o o o o o o o
Deliver overall sales growth in line with market growth. Deliver target sales growth in key markets. Ensure profitable launch of our own and our in-licensed products. Sales value growth at CER. Global sales and prescription share trends for key products and key markets. Number of life-cycle projects delivered. Number of successful launches of new products. Number of commercial collaborations secured. Active and rigorous development of our brands to maximise patient benefit and commercial potential. Driving high standards of sales force effectiveness, marketing excellence and